Barcelona, Spain (UroToday.com) Dr. Scott Tomlins opened this education session emphasizing that the goal of genomic tumor boards is to eventually not have genomic tumor boards. This statement reflects the need for cancer care providers to ultimately be able to incorporate genomic information into the routine care of patients. Genomic tumor boards evolve with time […]
Barcelona, Spain (UroToday.com) In this talk, Dr. Mark Rubin provided a summary of genomic-based tests that are available and provided a framework for understanding how to interpret some of these results. Sample acquisition for genomic testing can be done from multiple sites. For example, germline DNA can be obtained by cheek swab and can be […]
Barcelona, Spain (UroToday.com) In this educational session, Dr. De Bono discussed how prostate cancer genomic studies are important for the development of biomarkers to stratify disease. He broke these down into three categories: Pre-diagnosis, pre-treatment, and post-treatment. Pre-diagnosis biomarkers can include risk biomarkers such as germline DNA defects and diagnostic biomarkers such as prostate MRI […]
Barcelona, Spain (UroToday.com) Immune-checkpoint inhibitor therapy has yielded notable clinical benefits for patients with metastatic renal cell carcinoma (mRCC). 1,2 ADATPeR is the first prospective study evaluating the role of anti-PD1 agents in the neoadjuvant setting prior to cytoreductive nephrectomy in treatment-naïve patients with metastatic clear cell renal cell carcinoma. At ESMO 2019 clinical congress, […]
To test the effect of radical cystectomy (RC) with chemotherapy vs only chemotherapy on overall mortality (OM) in metastatic urothelial carcinoma of the urinary bladder (mUCUB). Within the Surveillance, Epidemiology, and End Results registry (2004-2016), we identified patients with mUCUB. Stratification was made according to treatment: RC with chemotherapy vs only chemotherapy. Kaplan-Meier plots and […]
GemRIS, an implantable drug delivery system from Taris Biomedical that delivers continuous intravesical gemcitabine, shows potential for use in multiple bladder cancer settings. Ongoing and recently completed phase 1 trials in non-muscle-invasive as well as muscle-invasive bladder cancer are yielding promising preliminary results. European urology focus. 2019 Sep 24 [Epub ahead of print] Dominic C […]
A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)-Targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD) Condition: Prostate Cancer Metastatic Intervention: Drug: cabazitaxel XRP6258 Drug: enzalutamide Drug: abiraterone acetate Drug: prednisone Purpose: Primary Objective: To compare the radiographic […]
Antibiotic use alters commensal gut microbiota, which is a key regulator of immune homeostasis. To investigate the impact of antibiotic use on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with systemic agents. We analyzed two cohorts: an institutional cohort (n=146) receiving programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1)-based immune checkpoint […]
Thermal ablation of small renal masses is increasingly accepted as an alternative to partial nephrectomy, particularly in patients with multiple comorbidities. Many professional societies support this alternate treatment with updated guidelines. Before performing thermal ablation, it is important to stratify risk and assess technical feasibility by evaluating tumor imaging features such as size, location, and […]
This study evaluated the clinical significance of pathological factors associated with T3a upstaging according to the American Joint Committee on Cancer/Union for International Cancer Control 8th edition TNM-staging system in patients with clinical T1 renal cell carcinoma undergoing definitive surgery. We retrospectively investigated 418 patients with renal cell carcinoma who underwent partial or radical nephrectomy […]
